KR940009163A - 벤질리덴 유도체 - Google Patents

벤질리덴 유도체 Download PDF

Info

Publication number
KR940009163A
KR940009163A KR1019930022532A KR930022532A KR940009163A KR 940009163 A KR940009163 A KR 940009163A KR 1019930022532 A KR1019930022532 A KR 1019930022532A KR 930022532 A KR930022532 A KR 930022532A KR 940009163 A KR940009163 A KR 940009163A
Authority
KR
South Korea
Prior art keywords
lower alkyl
compound
hydrogen
substituted
cycloalkyl
Prior art date
Application number
KR1019930022532A
Other languages
English (en)
Other versions
KR100281490B1 (ko
Inventor
사이찌 마쯔모또
다쯔오 쯔리
마사나오 이나가끼
히로꾸니 죠야마
Original Assignee
시오노 요시히꼬
시오노기 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노 요시히꼬, 시오노기 세이야꾸 가부시끼가이샤 filed Critical 시오노 요시히꼬
Publication of KR940009163A publication Critical patent/KR940009163A/ko
Application granted granted Critical
Publication of KR100281490B1 publication Critical patent/KR100281490B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
    • C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

하기 일반식(I)로 나타내는, 소염 활성을 갖는 벤질리덴 유도체：
상기식에서, A는 -CH2- 또는 -CH2CH2-이고, B는 결합 또는 -CH2-, -CHOH-, -CO-, -O-이거나 또는 A와 B는 함께 결합되어 -CH=CH-를 형성할 수 있고, D는 >N- 또는 >CH-이고, R1및 R2는 각각 독립적으로 수소, 저급알킬 또는 저급알콕시 이며, R3은 수소, 저급알킬, 사이클로알킬, 저급 알콕시, 아릴알킬옥시, 헤테로아릴알킬옥시, 저급 알킬카보닐, 아릴카보닐, 치환되거나 비치환된 카바모일, 또는 일반식 -(CH2)m-R4의 그룹이고, R4는 수소, 하이드록시, 치환되거나 비치환된 아미노, 아릴, 헤테로아릴, 하이드록시카보닐 또는 저급 알킬 옥시카보닐이며, n은 0 내지 3의 정수이다.

Description

벤질리덴 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 하기 일반식(I)의 화합물：
    상기식에서, A는 -CH2- 또는 -CH2CH2-이고, B는 결합 또는 -CH2-, -CHOH-, -CO-, -O-이거나 또는 A와 B는 함께 결합되어 -CH=CH-를 형성할 수 있고, D는 >N- 또는 >CH-이고, R1및 R2는 각각 독립적으로 수소, 저급알킬 또는 저급알콕시 이며, R3은 수소, 저급알킬, 사이클로알킬, 저급 알콕시, 아릴알킬옥시, 헤테로아릴알킬옥시, 저급 알킬카보닐, 아릴카보닐, 치환되거나 비치환된 카바모일, 또는 일반식 -(CH2)m-R4의 그룹이고, R4는 수소, 하이드록시, 치환되거나 비치환된 아미노, 아릴, 헤테로아릴, 하이드록시카보닐 또는 저급 알킬 옥시카보닐이며, n은 0 내지 3의 정수이다.
  2. 제1항에 있어서, R1및 R2가 각각 3급-부틸인 화합물.
  3. 제1항 또는 제2항에 있어서, A가 -CH2-이고, B가 -CH2-이며, D가 >N-인 화합물.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, R3가 저급 알킬 또는 사이클로알킬인 화합물.
  5. 활성 성분으로서 제1항에 청구된 화합물을 함유하는 소염제.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019930022532A 1992-10-28 1993-10-27 벤질리덴 유도체 KR100281490B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28997292 1992-10-28
JP289972/1992 1992-10-28

Publications (2)

Publication Number Publication Date
KR940009163A true KR940009163A (ko) 1994-05-20
KR100281490B1 KR100281490B1 (ko) 2001-02-15

Family

ID=17750115

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930022532A KR100281490B1 (ko) 1992-10-28 1993-10-27 벤질리덴 유도체

Country Status (14)

Country Link
US (1) US5418230A (ko)
EP (1) EP0595546B1 (ko)
KR (1) KR100281490B1 (ko)
CN (1) CN1035614C (ko)
AT (1) ATE135697T1 (ko)
AU (1) AU675078B2 (ko)
CA (1) CA2109498A1 (ko)
DE (1) DE69301894T2 (ko)
DK (1) DK0595546T3 (ko)
ES (1) ES2089736T3 (ko)
GR (1) GR3019395T3 (ko)
HU (1) HU215924B (ko)
NO (1) NO303828B1 (ko)
TW (1) TW378207B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3507124B2 (ja) * 1993-05-26 2004-03-15 塩野義製薬株式会社 ベンジリデン誘導体の製造法
DE19700061A1 (de) * 1997-01-03 1998-07-09 Hoechst Schering Agrevo Gmbh Verfahren zur Herstellung von cyclischen N-Aminosulfonamiden
BR9812982A (pt) * 1997-10-24 2000-08-08 Shionogi & Co Agente anti-reumático
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
CN1343119A (zh) 1999-01-21 2002-04-03 盐野义制药株式会社 延缓酚羟基化合物变色的药用组合物
JP2004510705A (ja) 2000-07-20 2004-04-08 ラウラス　エイエス 方法
WO2002080974A1 (fr) * 2001-04-04 2002-10-17 Sankyo Company, Limited Utilisation medicale d'inhibiteur de production de cytokine
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
KR20090118994A (ko) 2002-12-13 2009-11-18 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
ES2576292T7 (es) 2006-03-17 2022-08-24 Univ Johns Hopkins Derivados de N-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiológicamente útiles
UA94979C2 (uk) 2006-12-22 2011-06-25 Рекордати Айеленд Лимитед КОМБІНОВАНА ТЕРАПІЯ ПОРУШЕНЬ НИЖНІХ СЕЧОВИВІДНИХ ШЛЯХІВ ЛІГАНДАМИ α2δ І НПЗП
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066571B2 (ja) * 1985-05-09 1994-01-26 エーザイ株式会社 ２−ピロリドン誘導体
PT83152B (pt) * 1985-08-09 1989-03-30 Lilly Co Eli Processo para a preparacao de compostos di-t-butilfenoicos
DE68907095T2 (de) * 1988-03-21 1994-01-05 Boehringer Ingelheim Pharma Verbindungen zur Verhinderung der Biosynthese von der Lipoxygenase abgeleiteten Metaboliten der Arachidonsäure.
FI93954C (fi) * 1988-11-29 1995-06-26 Warner Lambert Co Menetelmä lääkeaineina käyttökelpoisten 3,5-di-tert-butyyli-4-hydroksifenyylisubstituoitujen 1,2,4- ja 1,3,4-tiadiatsolien sekä oksadiatsolien ja triatsolien valmistamiseksi
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
IL108962A (en) * 1989-12-21 1996-12-05 Lilly Co Eli Use of hydrocarbon-containing sulfur-containing heterocyclic histories, process for their preparation and pharmaceutical preparations containing them
US5319099A (en) * 1991-01-21 1994-06-07 Shionogi Seiyaku Kabushiki Kaisha 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents

Also Published As

Publication number Publication date
US5418230A (en) 1995-05-23
ATE135697T1 (de) 1996-04-15
TW378207B (en) 2000-01-01
GR3019395T3 (en) 1996-06-30
NO933870D0 (no) 1993-10-27
AU675078B2 (en) 1997-01-23
KR100281490B1 (ko) 2001-02-15
ES2089736T3 (es) 1996-10-01
HU9303053D0 (en) 1994-01-28
CA2109498A1 (en) 1994-04-29
EP0595546B1 (en) 1996-03-20
DE69301894T2 (de) 1996-11-07
DK0595546T3 (da) 1996-04-15
CN1092414A (zh) 1994-09-21
NO303828B1 (no) 1998-09-07
DE69301894D1 (de) 1996-04-25
HU215924B (hu) 1999-03-29
CN1035614C (zh) 1997-08-13
NO933870L (no) 1994-04-29
HUT70530A (en) 1995-10-30
AU4910793A (en) 1994-05-12
EP0595546A1 (en) 1994-05-04

Similar Documents

Publication Publication Date Title
KR930703243A (ko) 방향족 설폰아미드계 하이드록삼산 유도체
KR940009163A (ko) 벤질리덴 유도체
KR900018098A (ko) 피리돈 카르복실산과 항균제
KR930002325A (ko) 피리미딘 유도체
KR930703303A (ko) 1, 4-벤조티아제핀 유도체
KR950000693A (ko) 프로펜산 유도체
ECSP034660A (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
NO950009D0 (no) Heterocykliske forbindelser som farmasöytika
KR927003540A (ko) 3-벤질리덴-1-카르바모일-2-피롤리돈 유사체
DE69412476T2 (de) Vitamin-d-amid-derivate
KR920012051A (ko) 비페닐릴 화합물
CA2040517A1 (en) 1,8-naphthyridin-2-one derivatives
KR920000746A (ko) 아미노벤조디아제핀
DK5386A (da) Arylcyklobutylaminer og laegemiddelpraeparat indeholdende en saadan forbindelse
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
KR950008468A (ko) 방향족 카복실산 유도체
KR900016098A (ko) 카페인산의 유도체 및 이를 함유하는 약제학적 조성물
ATE205469T1 (de) Phenylbenzoesäureester-derivate und flüssigkristallzubereitungen
KR890016017A (ko) 치환된 1-(1h-이미다졸-4-일)알킬-벤즈아미드
KR860700250A (ko) 신규 아미딘 화합물
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
KR900001715A (ko) Bu-3608 유도체
KR900018131A (ko) 이합체 에피포도필로톡신 글루코사이드 유도체
KR890003793A (ko) 3'-데메톡시에피포도필로톡신 배당체의 유도체
KR890001939A (ko) 나프탈렌 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20041109

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee